GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Selling, General, & Admin. Expense

MAPI (Mapi - Pharma) Selling, General, & Admin. Expense : $3.08 Mil (TTM As of Jun. 2015)


View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Mapi - Pharma's selling, general, & admin. expense for the six months ended in Jun. 2015 was $1.40 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2015 was $3.08 Mil.


Mapi - Pharma Selling, General, & Admin. Expense Historical Data

The historical data trend for Mapi - Pharma's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma Selling, General, & Admin. Expense Chart

Mapi - Pharma Annual Data
Trend Dec12 Dec13 Dec14
Selling, General, & Admin. Expense
1.93 2.03 3.34

Mapi - Pharma Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15
Selling, General, & Admin. Expense - - 1.66 1.68 1.40

Competitive Comparison of Mapi - Pharma's Selling, General, & Admin. Expense

For the Drug Manufacturers - Specialty & Generic subindustry, Mapi - Pharma's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mapi - Pharma's Selling, General, & Admin. Expense Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mapi - Pharma's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Mapi - Pharma's Selling, General, & Admin. Expense falls into.



Mapi - Pharma Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2015 adds up the semi-annually data reported by the company within the most recent 12 months, which was $3.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mapi - Pharma  (NAS:MAPI) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Mapi - Pharma Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Mapi - Pharma Business Description

Industry
Traded in Other Exchanges
N/A
Address
Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.

Mapi - Pharma Headlines